Search clinical trials for: OBP-301

Total 5076 results

Ixaka Ltd
Andalusian Network for Design and Translation of Advanced Therapies

Terminated

The Efficacy and Safety of REX-001 to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Critical Limb Ischemia (CLI) | Peripheral Arterial Disease (PAD) | Diabetes Mellitus (DM)

Spain, Czechia, Portugal, Hungary, Germany, Poland
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Otherwise Healthy Overweight or Obese

United States
Hutchison Medipharma Limited

Completed

Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor

Cancer

China
Olympus Corporation

Terminated

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema

Emphysema

Japan
Proteon Therapeutics

Withdrawn

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

Peripheral Artery Disease

United States
Dynavax Technologies Corporation

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Healthy

United States
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
X4 Pharmaceuticals
Covance

Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Healthy

United States
Celgene

Completed

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, Slovakia, Poland, Bulgaria, Hungary
Auris Medical, Inc.

Completed

AM-101 in the Treatment of Acute Tinnitus 2 (TACTT2)

Tinnitus

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

Presumptive NAFLD

United States
Arava Bio Tech Ltd.
Cato Research

Unknown

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

Wounds and Injuries

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)

Chronic Kidney Disease

United States
Proteon Therapeutics

Completed

A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Chronic Kidney Disease

United States
Xenon Pharmaceuticals Inc.

Completed

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Inherited Erythromelalgia | Primary Erythromelalgia

Netherlands
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess VB-201 in Patients With Psoriasis

Active Plaque Psoriasis

United States, Germany, Israel
Vicept Therapeutics, Inc.
Accenture

Completed

Dose Response Study of Patients With Erythematous Rosacea

Erythematous (Type One) Rosacea

United States
Zelos Therapeutics

Withdrawn

A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)

Hip Fracture

United States
Sensorion

Not yet recruiting

A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations (AUDIOGENE)

Otorhinolaryngologic Diseases | Ear Diseases | Hearing Disorders | Deafness | Hearing Loss, Sensorineural | Congenital Deafness | DFNB9 | OTOF Gene Mutation

France
Mozart Therapeutics Australia Pty Ltd

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Type 1 Diabetes | Celiac Disease | Healthy Volunteers

Australia
CorrectSequence Therapeutics Co., Ltd

Recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China
Motric Bio

Recruiting

Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals

Stroke | Multiple Sclerosis | Cerebral Palsy | Spinal Cord Injuries | Dystonia | Muscle Spasticity | Hereditary Spastic Paraplegia | Hypertonia, Muscle

United States
Children's Hospital of Fudan University
CorrectSequence Therapeutics Co., Ltd

Recruiting

Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major

Beta-Thalassemia

China
Alumis Inc

Recruiting

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus (LUMUS)

SLE

United States, Argentina, Bulgaria, Colombia, Georgia, India, Mexico, Peru, Philippines, Poland, Spain, United Kingdom, Croatia, Denmark, Germany, Hungary, Korea, Republic of, Romania, Taiwan, Chile
Tvardi Therapeutics, Incorporated

Recruiting

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Transposon Therapeutics, Inc.

Recruiting

TPN-101 in Aicardi-Goutières Syndrome (AGS)

Aicardi-Goutières Syndrome (AGS)

United Kingdom, France, Italy
Wugen, Inc.

Recruiting

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States, Australia
Taivex Therapeutics Corporation

Recruiting

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

Lymphoma | Advanced Solid Tumor

Taiwan
Corat Therapeutics Gmbh

Recruiting

Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19

Covid19

Germany
n-Lorem Foundation
Mayo Clinic

Active, not recruiting

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Amyotrophic Lateral Sclerosis

United States
OXOLIFE

Completed

Phase II Clinical Trial to Evaluate the Ongoing Pregnancy Rate With OXO-001 in IVF/ICSI With Donor Oocytes. (OXOART2)

Infertility | Infertility, Female

Czechia, Spain, Poland
Red Queen Therapeutics, Inc.
PPD

Completed

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

COVID-19 | Infectious Disease | SARS CoV 2 Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed

United States
Canadian Cancer Trials Group
Canadian Cancer Society (CCS); ATGen Canada Inc; Ontario Institute for Cancer... and other collaborators

Active, not recruiting

Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO)

Covid-19 | Cancer

Canada
Regeneron Pharmaceuticals

Available

Compassionate Use of Vidutolimod
Auris Medical AG

Completed

AM-101 in the Treatment of Acute Tinnitus 3 (TACTT3)

Tinnitus

Germany
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Completed

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

China
Equilibre Biopharmaceuticals B.V.

Active, not recruiting

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Epilepsy

United States, Israel
Chong Kun Dang Pharmaceutical

Completed

Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects

Hypertension

Korea, Republic of
Sarkana Pharma Inc

Terminated

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

Healthy Participants

Netherlands
Neurotech Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

Macular Telangiectasia Type 2

United States, Australia, Germany
Neurotech Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Macular Telangiectasia Type 2

United States, United Kingdom, Australia, France
Aarhus University Hospital

Completed

A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.

Hidradenitis Suppurativa

Denmark
1ST Biotherapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

United States
101 Therapeutics

Active, not recruiting

Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Virus Diseases | COVID-19 | Infectious Disease | Glucocorticoids Toxicity

India
Basking Biosciences, Inc.

Completed

Study of DTRI-031 in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics | Pharmacodynamics

Australia
Yaqrit Ltd
Assistance Publique - Hôpitaux de Paris; IRCCS Azienda Ospedaliero-Universitaria... and other collaborators

Withdrawn

Safety and Tolerability of Yaq-001 in Patients With Non-Alcoholic Steatohepatitis

Non-Alcoholic Steatohepatitis

France, Italy, Portugal, Spain, Switzerland, United Kingdom
Bioventus LLC

Active, not recruiting

Safety Study of PTP-001 for Treating Knee Osteoarthritis

Knee Osteoarthritis

United States
Pfizer

Completed

Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States
Pfizer

Completed

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty

Scar Prevention

United States

Search clinical trials for: OBP-301

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations